Posts Tagged ‘life sciences’
It shouldn’t be surprising that Entagen, which makes the semantically-enabled Big Data analytics and collaboration engine TripleMap, has had its sights set on the life sciences space. CEO Christopher Bouton has his Ph.D in molecular neurobiology and has worked at a number of bio tech firms, as well as been the head of integrative data mining at Pfizer – a company that’s using TripleMap for visualized knowledge maps of associations between domain-specific entities (see our story here).
“We see some really compelling and exciting applications of this type of technology in the life sciences space,” says Bouton. But TripleMap can be applied to any scenario where Big Data dots must be connected so that users can collaborate around the understanding of the associations between entities – health care, legal, retail and finance all come to mind.
Big Data Startup Ayasdi Launches; Machine Learning Platform Combines Computer Science And Topological Data Analysis
This week a new Big Data startup company launched, Ayasdi, co-founded by Stanford mathematics professor Gunner Carlsson and based on his DARPA-funded research in the area of applied topology, with $10+million in Series A funding led by Khosla Ventures and Floodgate.
The technology, dubbed the Insight Discovery platform, is explained to be the “first machine learning platform that combines computer science and a branch of mathematics known as Topological Data Analysis (TDA) that visualizes the entire dataset.” Hundreds of machine learning algorithms, it says, go to work exploring datasets to in minutes automatically discover insights that can’t be determined through query-based or ad hoc approaches.
Semantic Tech: It’s Moving Mainstream, Playing To The Data-Is-An-Asset Crowd, And Living Life Out Loud
At the recent SemTech conference in NYC, The Semantic Web Blog had an opportunity to ask some leaders in the field about where semantic technology has been, and where it’s going.
David Wood, CTO, 3RoundStones:
The short take: Hiring has been on in a big way at semantic tech players as enterprises are moving in greater numbers to buy semantic software, recognizing their traditional vendors won’t solve their interoperability issues. Sem tech vendors should have a happy 2013 as semantics continues going mainstream.
The full take:
A new paper has been published entitled “Systems Chemical Biology and the Semantic Web: What They Mean for the Future of Drug Discovery Research.” The paper was written by David Wild, Ying Ding, Amit Sheth, Lee Harland, Eric Gifford, and Michael Lajiness. It can be downloaded for a fee of $27.95. According to the abstract, “Systems chemical biology, the integration of chemistry, biology and computation to generate understanding about the way small molecules affect biological systems as a whole, as well as related fields such as chemogenomics, are central to emerging new paradigms of drug discovery such as drug repurposing and personalized medicine.” Read more
Bioinformatics software provider IO Informatics recently released its free Knowledge Explorer Personal Edition. Version 3.6 of the Personal Edition can handle most of what Knowledge Explorer Professional 3.6, launched in October, can, but it does all its work in memory without direct connectivity to a back-end database.
“In particular, a lot of the strengths of Knowledge Explorer have to do with modeling data as RDF and then testing queries, visualizing and browsing the data to see that you have the ontologies and data mappings you need for your integration and application requirements.” says Robert Stanley, IO Informatics president and CEO. The Personal version is aimed at academic experts focused on data integration and semantic data modeling, as well as personal power users in life sciences and other data-intensive industries, or anyone who wants to learn the tool in anticipation of leveraging their enterprise data sets for collaboration and integration projects.
A few months ago FeirceBiotechIT named five biotech IT firms to watch, and they haven’t been disappointed with what they’ve seen: “This report gives FierceBiotechIT a chance to feature 5 software groups that are addressing a range of different needs for biotechs and other life sciences firms. Here you’ll find a Silicon Valley upstart taking on big competitors with new technology for integrating data from disparate sources and providing developers with insights about their clinical trials. There’s a Boston-area company using advanced analytics to spot biomarkers and other tantalizing details about health with the aid of supercomputing technology. And another group based in the U.K. has been quietly growing with R&D software originally licensed from Merck.” Learn more about the five companies here. Read more
This video lecture discusses the development of OpenTox, an open source predictive toxicology framework. The description states, “A new paradigm of 21st century human-oriented safety testing approaches is now emerging based on a combination of in silico and in vitro approaches. The new predictive test systems developed from this growing ‘grand challenge’ effort will need to combine evidences from a great variety of data, protocols, and concepts. The combination of these sources of knowledge within an ontology-based mechanistic knowledge-oriented framework to produce reliable test systems demands the development of a semantic web for toxicology.” Read more
NEXT PAGE >>